""This trial is unlikely to provide a conclusive answer either way as to the benefits of so-called puberty blockers," he said. "In this instance, puberty-blocking medication is being assessed as a standalone intervention. In reality, the real benefits of this treatment pathway are experienced after a patient has progressed on to gender-affirming hormones, allowing them to achieve the required puberty changes which will bring them into alignment with their gender identity.""
"The NHS Pathways trial, led by researchers from King's College London, will study the effectiveness of the drugs by focusing on the physical, social and emotional wellbeing of 220 youngsters over two years. Commissioned in the wake of the government's ban on the medication, the £10 million ($13.1 million) trial is the only way to access puberty blockers through the National Health Service."
The NHS Pathways trial will study the physical, social and emotional wellbeing effects of puberty blockers in 220 young people over two years. The £10 million trial was commissioned after a government ban and currently represents the only route to access puberty blockers through the NHS. Puberty blockers prevent or delay unwanted pubertal changes, are physically reversible, and have been used in the UK for about 35 years. Concern exists that assessing blockers as a standalone intervention may not capture benefits that appear after progression to gender-affirming hormones. Participants will complete around 50 questionnaires covering trauma and suicide and will undergo bodily examinations; half will receive immediate treatment while the other half will wait at least a year.
Read at PinkNews | Latest lesbian, gay, bi and trans news | LGBTQ+ news
Unable to calculate read time
Collection
[
|
...
]